GC Corp (006280.KS) Q1 2026: Operating Profit Surges 47% While Subsidiary Exit and Tax Reversal Drag Net Income 31% Lower

Blood product exports and vaccine sales power the strongest operating performance in years, but a ₩14 billion adverse tax swing and the deconsolidation of GC Wellbeing cut controlling shareholders' net income nearly a third.

Source: Q1 2026 Quarterly Report (58th Fiscal Year, January–March 2026) — Filed May 15, 2026 with DART | Consolidated Financial Statements | Unit: ₩ billions